Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;187(6):838.
doi: 10.1111/bjd.21880. Epub 2022 Oct 5.

How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?

Stephanie J Lax  1 , Aaron M Drucker  2   3
Affiliations
Comment

How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?

Stephanie J Lax et al. Br J Dermatol. 2022 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Landis M, Arya M, Smith S et al. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol 2022; 187:878-87.
    1. OPZELURA™ (ruxolitinib) [prescribing information]. Available at: https://www.opzelura.com/prescribing-information.pdf (last accessed 14 September 2022).
    1. Williams H. New topical treatments for atopic dermatitis: active comparators are needed. J Am Acad Dermatol 2021; 85:1065-6.
    1. Williams HC, Schmitt J, Thomas KS et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol 2022; 149:1899-911.
    1. Steele L, Stuart B, Axon E et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst Rev 2022; 7:CD015064.